日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A clinical practice guideline for tuberculous meningitis

结核性脑膜炎临床实践指南

Donovan, Joseph; Cresswell, Fiona V; Tucker, Elizabeth W; Davis, Angharad G; Rohlwink, Ursula K; Huynh, Julie; Solomons, Regan; Seddon, James A; Bahr, Nathan C; van Laarhoven, Arjan; Anderson, Suzanne T; Jain, Sanjay K; Chow, Felicia C; Pattison, Sophie; Scriven, James E; Singh, Gabriela; Aarnoutse, Rob E; Alffenaar, Jan-Willem C; Dian, Sofiati; Manesh, Abi; Basu Roy, Robin; Singh, Varinder; van Toorn, Ronald; Upton, Caryn M; van Crevel, Reinout; Dooley, Kelly E; Gibb, Diana; Meya, David; Wilkinson, Robert J; Rogozińska, Ewelina; Misra, Usha K; Figaji, Anthony; Thwaites, Guy E

Saliva as an Alternative Matrix for Pharmacokinetic Research and Therapeutic Drug Monitoring of the Antituberculosis Drug Pyrazinamide

唾液作为抗结核药物吡嗪酰胺药代动力学研究和治疗药物监测的替代基质

Ndaro, Arnold J; Semvua, Hadija H; Mtabho, Charles M; Heijens, Claudia A W; Te Brake, Lindsey H M; Kibiki, Gibson S; Aarnoutse, Rob E

Population Pharmacokinetic Modeling of Standard- and High-Dose Rifampicin for Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial

2R2随机对照试验中标准剂量和高剂量利福平用于结核病预防治疗的群体药代动力学模型

Gafar, Fajri; Svensson, Elin M; Yunivita, Vycke; Fregonese, Federica; Fisher, Dina; Fox, Greg J; Nguyen, Thu Anh; Nguyen, Binh Hoa; Johnston, James; Long, Richard; Valiquette, Chantal; Aarnoutse, Rob E; Ruslami, Rovina; Menzies, Dick

Pharmacogenetics and Pharmacokinetics of Moxifloxacin in MDR-TB Patients in Indonesia: Analysis for ABCB1 and SLCO1B1.

印度尼西亚耐多药结核病患者莫西沙星的药物遗传学和药代动力学:ABCB1 和 SLCO1B1 分析

Annisa Nurul, Afifah Nadiya N, Santoso Prayudi, Yunivita Vycke, Te Brake Lindsey H M, Aarnoutse Rob E, Barliana Melisa I, Ruslami Rovina

Optimizing Nortriptyline Dosing: A Comparison between Pharmacogenetics-Based, Phenotype-Based, and Standard Dosing

优化去甲替林剂量:基于药物遗传学、基于表型和标准剂量方案的比较

Vos, Cornelis F; Coenen, Marieke J H; Ter Hark, Sophie E; Schellekens, Arnt F A; Aarnoutse, Rob E; Janzing, Joost G E; Ter Heine, Rob

Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB

贝达喹啉、德拉马尼和莫西沙星联合或不联合不同剂量的舒特唑胺或德尔帕唑胺治疗药物敏感性结核病的安全性

Koele, Simon E; Stoycheva, Krista; Mtweve, Cyprian; Manyama, Christina; Mpagama, Stellah; Mhimbira, Francis; Wallis, Robert; Ntinginya, Nyanda Elias; Liyoyo, Alphonce; Huglin, Beno; Minja, Lilian Tina; Wagnerberger, Larissa; Zumba, Tresphory; Noreña, Ivan; Peter, Daud D; Beattie, Trevor; Makkan, Heeran; Sloan, Derek J; Te Brake, Lindsey; Aarnoutse, Rob E; McHugh, Timothy D; Wildner, Leticia; Schildkraut, Jodie; Aldana, Brian H; Phillips, Patrick P J; Hoelscher, Michael; Svensson, Elin M; Heinrich, Norbert

Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043

抗结核药物 BTZ-043 的群体药代动力学和暴露-反应关系

Koele, Simon E; Heinrich, Norbert; De Jager, Veronique R; Dreisbach, Julia; Phillips, Patrick P J; Gross-Demel, Petra; Dawson, Rodney; Narunsky, Kim; Wildner, Leticia M; Mchugh, Timothy D; Te Brake, Lindsey H M; Diacon, Andreas H; Aarnoutse, Rob E; Hoelscher, Michael; Svensson, Elin M

Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology

研究肺内结核病治疗药物的药代动力学:方法学的系统评价

van der Feltz, Isabella; Wen, Haini; Aarnoutse, Rob E; Magis-Escurra, Cecile; Svensson, Elin M; Te Brake, Lindsey H M

Population pharmacokinetics and optimized dosing of cefuroxime in critically ill patients

危重患者头孢呋辛的群体药代动力学及优化给药方案

Mouton, Jaap W A; Machiels, Julian D; Pistorius, Arthur M A; Ter Heine, Rob; Frenzel, Tim; Jager, Nynke G L; Schouten, Jeroen A; Janssen, Paddy K C; Aarnoutse, Rob E; Brüggemann, Roger J

Correction: A genetic risk score to predict treatment nonresponse in psychotic depression

更正:用于预测精神病性抑郁症治疗无反应的遗传风险评分

Ter Hark, Sophie E; Coenen, Marieke J H; Vos, Cornelis F; Aarnoutse, Rob E; Nolen, Willem A; Birkenhager, Tom K; van den Broek, Walter W; Schellekens, Arnt F A; Verkes, Robbert-Jan; Janzing, Joost G E